DanielSDickersonMDPhD, FAAFP

Research • Lenexa, KS

Medical Director / Principal Investigator Phase 1 & Phase 2 Clinical Research Trials

Join to view full profile

Dr. Dickerson is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Dickerson's full profile

Already have an account?

Office
9755 Ridge Dr
Lenexa, KS 66219
Phone+1 913-410-2973

Fax+1 913-599-2753

Summary

Dr. Daniel Dickerson is a medical professional based in Lenexa, KS, with a specialty in research and substantial experience in family medicine. He holds an MD from the University of Kansas School of Medicine and a PhD in Chemistry-Biochemistry from the University of Missouri. His career includes roles as Medical Director/Principal Investigator at ICON Clinical Research since 2014, Clinical Instructor at the University of Kansas School of Medicine, and a Family Physician at both LMH Health and AdventHealth Shawnee Mission. Dr. Dickerson has experience in conditions like atherosclerosis, diabetic neuropathy, Alzheimer's disease, COPD, and cystic fibrosis. He has authored several research publications on topics including pharmacokinetics and pharmacodynamics and has been involved in multiple clinical trials. His accolades include awards such as the Rainbow Award, Preceptor of the Year, and Teacher Development Award.

Education & Training

University of Kansas School of MedicineResidency, Family Medicine, 1996 - 1999
University of Kansas School of MedicineClass of 1996
University of MissouriPhD, Chemistry-Biochemistry, 1987 - 1994

Certifications & Licensure

KS State Medical License 1999 - 2025

Awards, Honors, & Recognition

Rainbow Award (Hero in Medicine) Kansas University School of Medicine, 2006
Preceptor of the Year Kansas University School of Medicine, 2012
Teacher Development Award American Academy of Family Physicians Foundation, 2005
Medical Student Education Recognition Award University of Kansas School of Medicine, 2005
Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2011
Join now to see all

Clinical Trials

Bioequivalence of Duvelisib and Food Effect on Pharmacokinetics of IPI-145 Start of enrollment: 2014 Nov 01
Completed
Phase 1
Study of PF614 Compared to OxyContin® in Healthy Volunteers Start of enrollment: 2016 Nov 16
Completed
Phase 1
A Study to Investigate the Safety, Tolerability and Pharmacokinetics of SUVN-D4010 in Healthy Subjects Start of enrollment: 2015 Jul 01
Completed
Phase 1
A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer Start of enrollment: 2016 May 19
Active, not recruiting
Phase 2
A Study to Evaluate LY3202328 in Overweight Healthy Participants and Dyslipidemia Start of enrollment: 2016 Mar 01
Completed
Phase 1
A Study of EDP 305 in Healthy Subjects and Subjects With Presumptive NAFLD Start of enrollment: 2016 Sep 01
Completed
Phase 1
A Study to Investigate the Effect of Food, Gender, and Age on the Pharmacokinetic Profile of SUVN-D4010 in Healthy Subjects Start of enrollment: 2017 Jan 23
Completed
Phase 1
Drug-drug Interaction Study Between EDP-305, Midazolam, Caffeine and Rosuvastatin in Healthy Volunteers. Start of enrollment: 2017 May 11
Completed
Phase 1
A Study of EDP-938 in Healthy Subjects Start of enrollment: 2017 Dec 07
Completed
Phase 1
A Study to Evaluate the Single Dose Safety, Tolerability and Pharmacokinetics of IV BCX4430 Start of enrollment: 2018 Dec 10
Completed
Phase 1
A Study of EDP-514 in Healthy Subjects (Part 1) and Patients With Chronic Hepatitis B Virus Infection (Part 2) Start of enrollment: 2019 Jun 26
Completed
Phase 1
Drug-Drug Interaction Study Between EDP-938, Tacrolimus, Dabigatran, Rosuvastatin and Midazolam in Healthy Subjects Start of enrollment: 2020 Jul 08
Completed
Phase 1
A First-In-Human SAD and MAD Study to Evaluate the Safety, Tolerability, PK and PD of SC Administered ALTB-268 in Healthy Volunteers Start of enrollment: 2023 Jan 17
Completed
Phase 1
Join now to see all

Publications & Presentations

PubMed

First-in-Human Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of BMS-986308: A Renal Outer Medullary Potassium Channel Inhibitor.
Sharif I Soleman, Juan Maya, Paul Levesque, Atif Mohammad, Lisa Christopher
Clinical Pharmacology and Therapeutics. 2024-12-01
Clinical pharmacology and tolerability of REC-994, a redox-cycling nitroxide compound, in randomized phase 1 dose-finding studies.
Ron Alfa, Timothy Considine, Shafique Virani, Matt Pfeiffer, Anthony Donato
Pharmacology Research & Perspectives. 2024-06-01
5 citations
A Randomised Controlled Trial Comparing the Pharmacokinetics and Tolerability of the Proposed Adalimumab Biosimilar MSB11022 Delivered via Autoinjector and Pre-filled ...
Ahad Sabet, Daniel S Dickerson, Eugenia E Kunina, Anna Lucia Buccarello, Joëlle Monnet
Rheumatology and Therapy. 2022-04-01

Committees

Chairman, Kansas Academy of Family Physicians Governmental Advocacy Committee 2015 - 2020
School Board Member, Eudora Board of Education 2011 - 2015
Chief of Family Medicine, Lawrence Memorial Hospital Executive Committee 2005 - 2009

Professional Memberships

American Academy of Family Physicians - AAFP
Fellow

Industry Relationships

Research Physician, ICON Clinical Research (legacy PRA HealthScences)2014 - Present